Table 4.
Correlation of adverse events in hypophysitis with the four immune checkpoint inhibitors.
| Immune checkpoint inhibitor | Case | Non-case | ROR | ROR025 | ROR975 |
|---|---|---|---|---|---|
| Nivolumab | 419 | 114284 | 289.58 | 258.49 | 324.40 |
| Pembrolizumab | 149 | 57928 | 171.74 | 144.91 | 203.54 |
| Ipilimumab | 643 | 28420 | 2248.57 | 2025.31 | 2496.45 |
| Atezolizumab | 41 | 22169 | 97.29 | 71.28 | 132.79 |
Case: number of cases of hypophysitis; Non-case: number of cases of non-hypophysitis; ROR: reporting odds ratio; ROR025: lower limit of the ROR 95% confidence interval; ROR975: upper limit of the ROR 95% confidence interval.